Quantcast
Last updated on April 23, 2014 at 17:35 EDT

Latest Tyrosine kinase 2 Stories

2012-09-10 11:09:18

Researchers find new risk regions associated with primary biliary cirrhosis Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25. The team used a DNA microchip, called Immunochip, to survey more thoroughly regions of the genome known to underlie other autoimmune diseases to discover if they play a role also in PBC...

2012-06-08 06:25:57

BERLIN, June 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology [EULAR...

2011-10-05 22:03:16

Described in Journal of Interferon & Cytokine Research A possible new target for breast cancer therapy comes from the discovery that the Tyk2 protein helps suppress the growth and metastasis of breast tumors, as reported in Journal of Interferon & Cytokine Research, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online for the next week at http://www.liebertpub.com/jir. Qifang Zhang and Andrew Larner, Virginia Commonwealth University...

2010-06-03 06:30:00

-Proceeds to support acceleration of CYT387 Phase II myelofibrosis study- MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010. Listing of the common shares sold has been approved by the NYSE Amex...

2010-04-13 14:21:49

Identification could lead to the development of new therapies Investigators from Hospital for Special Surgery have identified a pathway involved in turning off inflammation that does not work properly in people with inflammatory arthritis. The finding, reported in the April 23 issue of the journal Immunity, could lead to the development of new therapeutic approaches to treating arthritis in the future. "This is the first study to link this pathway to rheumatoid arthritis. In the twenty years...